VIR-5818 is under clinical development by Vir Biotechnology and currently in Phase II for Metastatic Breast Cancer. According to GlobalData, Phase II drugs for Metastatic Breast Cancer have a 32% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how VIR-5818’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VIR-5818 overview
AMX-818 is under development for the treatment of HER2 low expressing and EGFR positive solid tumors including breast cancer, colorectal cancer. It acts by targeting HER2 and CD3. The drug candidate comprises XTEN polypeptide fused HER2 scfv and CD3 scfv linked as a single polypeptide. The drug candidate is a bi-specific monoclonal antibody being developed based on the XPAT (XTENylated Protease-Activated T Cell Engager) platform. It is administered by intravenous route. It was also under development for gastric cancer. It is a protease-activated prodrug T-cell-engager (TCE).
Vir Biotechnology overview
Vir Biotechnology (Vir) is an immunology company that focuses on cutting-edge technologies to treat infectious and viral-associated diseases. The company’s pipeline products includes tobevibart + elebsiran, which treats chronic hepatitis delta (CHD); elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a1, elebsiran + TLR82 + PD-13, for chronic hepatitis B; VIR-1388 and Cure: mAb combination, which targets human immunodeficiency virus (HIV); VIR-8190, which treats respiratory syncytial virus (RSV), human metapneumovirus (MPV); VIR-2981 (Influenza A+B) for Influenza; VIR-1949, which targets Pre-Cancerous HPV Lesions and VIR-7229, which treats coronavirus disease 2019 (COVID-19). The company’s proprietary monoclonal antibody (mAb) discovery platform, which enables the analysis database of human antibodies and delivers transformative medicines for disease and the T Cell-Based Viral Vector Platform, is used to develop vaccines for human immunodeficiency virus (HIV). Vir is headquartered in San Francisco, California, the US.
For a complete picture of VIR-5818’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
